Compare MasterCard Inc (MA) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Twist Bioscience Corp — how do they compare? MasterCard Inc trades at $544.46 (market cap $480.32B), while Twist Bioscience Corp trades at $87.45 (market cap $5.84B). The key difference: MasterCard Inc is far larger — about 82.2× Twist Bioscience Corp's market cap, and MasterCard Inc pays a 0.64% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| MA | TWST | |
|---|---|---|
Market Cap | $480.32B | $5.84B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $102.88 |
52-Week Low | $471.55 | $24.16 |
Enterprise Value | $491.06B | $5.77B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $546.36, up 0.51% on the day, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $4.60 exceeding the $4.41 estimate. Revenue grew to $32.79B in 2025, and net income margin remains high at 45.88%. Analysts maintain a strong buy consensus with a $634.27 price target, reflecting confidence in continued growth amid digital payment expansion.
Outlook is positive given earnings momentum and strategic AI initiatives, but risks include payment disruption from stablecoins and high valuation multiples. The stock offers growth potential with upside to consensus targets, though investors should monitor competitive threats and macroeconomic sensitivity.
Twist Bioscience (TWST) trades at $90.98, down 3.06% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Recent Q2 2026 earnings beat revenue estimates but missed on EPS, while analyst sentiment remains positive with 78.57% buy ratings and a $91.63 consensus target.
The outlook balances growth potential in synthetic biology and AI-driven drug discovery against persistent losses and cash burn. Key risks include execution challenges in achieving profitability and competitive pressures. With the stock near analyst targets, further upside depends on margin improvement and sustained top-line expansion in the genomics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
